Here are the 10-K annual reports from Lifevantage Corporation (LFVN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LFVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFVN filings page.
LifeVantage Corporation (LFVN) reports on its fiscal year ended June 30, 2026, highlighting a direct-selling nutrigenomics business focused on dietary supplements, skin and hair care, energy drinks, gut health, and pet products. The company operates primarily through independent consultants across the Americas, Asia/Pacific, and Europe.
Net revenue was $182.6 million, down from $228.5 million in 2025, with the Americas contributing 78.2% and Asia/Pacific & Europe 21.8%. U.S. sales represented about 74% of revenue and Japan about 13%. LFVN closed Hong Kong and Singapore on May 31, 2026 and expanded into Iceland and Portugal.
The company launched multiple new products and systems, including the patent-pending P84 System for gut health and the MindBody GLP-1 System for weight management, and integrated assets acquired from LoveBiome. It continued rolling out its “Evolve” compensation plan and expanded its Rewards Circle loyalty program. As of August 26, 2026, 12,527,348 common shares were outstanding; non-affiliate market value was approximately $63.7 million as of December 31, 2025. The filing outlines extensive regulatory, operational, technology, and direct-selling risks.
LifeVantage Corporation describes its direct-selling dietary supplement and personal-care business, emphasizing a nutrigenomics "activating wellness" strategy and product portfolio including Protandim4, TrueScience4 skin and hair care, AXIO4 energy drinks, Petandim4, and the patent-pending MindBody GLP-1 System42; MB Core42; MB Enhance42. The company reported approximately $220.0 million aggregate market value of common stock held by non-affiliates as of December 31, 2024 and 12,691,009 shares outstanding as of September 3, 2025. As of June 30, 2025 it employed 238 people and had ~51,000 active independent consultants (vs 49,000 in fiscal 2024). Approximately 22% of fiscal 2025 revenue was international, primarily Japan. There was no outstanding balance on the 2024 Credit Facility as of June 30, 2025; the facility matures April 12, 2027. The filing lists material risks including dependence on independent consultants, concentration on a few products, third-party manufacturing and supply-chain risks, regulatory and advertising scrutiny, cybersecurity and data-privacy obligations, potential tax or employment classification exposure for consultants, activist stockholder actions, and foreign currency and market-entry risks.